NASDAQ:CLOV - US18914F1030 - Common Stock
The current stock price of CLOV is 2.62 USD. In the past month the price decreased by -5.76%. In the past year, price decreased by -0.38%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
UNH | UNITEDHEALTH GROUP INC | 12.28 | 280.64B | ||
ELV | ELEVANCE HEALTH INC | 9.65 | 71.75B | ||
HUM | HUMANA INC | 15.3 | 36.52B | ||
CNC | CENTENE CORP | 5.63 | 14.26B | ||
MOH | MOLINA HEALTHCARE INC | 7.99 | 9.80B | ||
HQY | HEALTHEQUITY INC | 27.07 | 7.73B | ||
ALHC | ALIGNMENT HEALTHCARE INC | N/A | 3.24B | ||
PGNY | PROGYNY INC | 40.12 | 2.04B | ||
NEUE | NEUEHEALTH INC | N/A | 59.17M |
Clover Health Investments Corp. is a physician enablement technology company that provides Medicare Advantage plans in the United States. The company is headquartered in Jersey City, New Jersey and currently employs 570 full-time employees. The company went IPO on 2020-06-12. The firm is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.
CLOVER HEALTH INVESTMENTS CO
30 Montgomery Street
Jersey City NEW JERSEY 37067 US
CEO: Vivek Garipalli
Employees: 570
Phone: 12014322133
The current stock price of CLOV is 2.62 USD. The price decreased by -0.38% in the last trading session.
The exchange symbol of CLOVER HEALTH INVESTMENTS CO is CLOV and it is listed on the Nasdaq exchange.
CLOV stock is listed on the Nasdaq exchange.
11 analysts have analysed CLOV and the average price target is 3.34 USD. This implies a price increase of 27.31% is expected in the next year compared to the current price of 2.62. Check the CLOVER HEALTH INVESTMENTS CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CLOVER HEALTH INVESTMENTS CO (CLOV) has a market capitalization of 1.34B USD. This makes CLOV a Small Cap stock.
CLOVER HEALTH INVESTMENTS CO (CLOV) currently has 570 employees.
CLOVER HEALTH INVESTMENTS CO (CLOV) has a support level at 2.61 and a resistance level at 2.69. Check the full technical report for a detailed analysis of CLOV support and resistance levels.
The Revenue of CLOVER HEALTH INVESTMENTS CO (CLOV) is expected to grow by 23.9% in the next year. Check the estimates tab for more information on the CLOV EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CLOV does not pay a dividend.
CLOVER HEALTH INVESTMENTS CO (CLOV) will report earnings on 2025-11-04, after the market close.
CLOVER HEALTH INVESTMENTS CO (CLOV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
The outstanding short interest for CLOVER HEALTH INVESTMENTS CO (CLOV) is 10.17% of its float. Check the ownership tab for more information on the CLOV short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CLOV. While CLOV seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CLOV reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 69.23% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -7.5% | ||
ROE | -12.52% | ||
Debt/Equity | 0 |
11 analysts have analysed CLOV and the average price target is 3.34 USD. This implies a price increase of 27.31% is expected in the next year compared to the current price of 2.62.
For the next year, analysts expect an EPS growth of -36% and a revenue growth 23.9% for CLOV